Monitor for insider selling or short interest changes post-offering; assess clinical progress of Varseta-M in metastatic colorectal cancer as the key value driver. The stock may experience near-term pressure due to dilution despite the cash infusion.
Price Chart
Executive Summary
CytomX Therapeutics priced a public offering of 45,990,567 shares and pre-funded warrants for 1,179,245 shares at $5.30 per share, raising $250 million in gross proceeds. The company plans to use the funds primarily for the development of its lead asset Varseta-M and other pipeline programs, with a 30-day over-allotment option for up to an additional 7,075,471 shares.
Key Financial Metrics
Key Facts
- CytomX raised $250 million in gross proceeds through a public offering.
- Offering includes 45,990,567 common shares and pre-funded warrants for 1,179,245 shares, priced at $5.30 per share.
- Underwriters have a 30-day option to purchase up to an additional 7,075,471 shares.
- Proceeds will fund development of Varseta-M (CX-2051) and other pipeline assets, plus general corporate purposes.
- Closing expected on March 19, 2026, subject to customary conditions.
Financial Impact
$250 million gross proceeds, with potential for up to $38.5 million more if over-allotment is exercised (total ~$288.5M gross).
Risk Factors
- Significant shareholder dilution from issuance of nearly 47.2 million shares and warrants (pre- and post-over-allotment).
- Forward-looking use of proceeds with no guaranteed clinical or commercial success.
- Biotech market sensitivity to capital raises in absence of near-term catalysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257862 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 22, 2026 14w ago | 8-K | $3.15 $2.77 | ▼ −12.22% | ▼ −15.47% | $2.58 (−18.25%) |
Mar 18, 2026 28w ago | Press Release | $4.40 $2.98 | ▼ −32.27% | ▼ −43.80% | $2.58 (−41.48%) |
Mar 16, 2026 28w ago | Press Release | $5.45 $2.98 | ▲ +45.32% | ▲ +55.18% | $2.58 (+52.75%) |
Mar 16, 2026 28w ago | Press Release | $6.75 $2.94 | ▼ −56.44% | ▼ −66.93% | $2.58 (−61.85%) |
Mar 4, 2026 30w ago | Press Release | $5.07 $3.71 | ▼ −26.82% | ▼ −36.91% | $2.58 (−49.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access